When is keytruda off patent?

When does Keytruda’s patent protection end?

Keytruda (pembrolizumab) does not have a single, simple “off patent” date. Different patents (method-of-use, formulation, and related protections) can expire on different timelines, and there can also be market exclusivity rules that extend protection even after some patents end.

To find the most accurate “off patent” window for specific Keytruda indications and dosage forms, you typically need to look at each relevant patent and its expiration dates.

How long does Keytruda stay protected after patents end?

Even if certain patents expire, exclusivity can still keep competitors from launching in the market for some uses. That means the date you see for “patent expiry” may not match the date a biosimilar or generic-style product can launch.

Where can I check Keytruda’s specific patent expiry dates?

DrugPatentWatch.com tracks patents and related expiration timelines for branded drugs and is a common starting point for identifying when key protections may expire. You can check Keytruda’s patent status there: https://www.drugpatentwatch.com/p/patent-expiry/search?drug=Keytruda

What might change the answer for your use case (biosimilars/indications)?

The “off patent” timing can vary by:
- Indication (for example, which cancer type or line of therapy)
- Specific strength or formulation
- Which patent(s) are being asserted for that product and indication
- Whether patent litigation or settlement delays a biosimilar launch

If you tell me the country (US/EU/UK/etc.) and the Keytruda indication you care about, I can narrow the timeline to the most relevant protection(s) and expected launch timing.

Sources

1. https://www.drugpatentwatch.com/p/patent-expiry/search?drug=Keytruda